Amgen ١ مايو ٢٠٢٦ Amgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data - Fierce Biotech
Amgen ٢٩ أبريل ٢٠٢٦ Amgen, AstraZeneca join FDA effort harnessing cloud for real-time clinical trials - BioSpace
Amgen ٢٨ أبريل ٢٠٢٦ FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board - Fierce Biotech
Amgen ٢٨ أبريل ٢٠٢٦ FDA turns up heat on Amgen, proposing to rescind approval of Tavneos - Fierce Pharma
Amgen ٢٤ أبريل ٢٠٢٦ Amgen’s Chief Technology Officer Dr David Reese to retire - European Pharmaceutical Review
Amgen ٢٠ أبريل ٢٠٢٦ Zurcher Kantonalbank Zurich Cantonalbank Buys 55,333 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen ١٦ أبريل ٢٠٢٦ Federal Circuit Distinguishes Amgen in Reversal of Invalidation of Teva Headache Treatment Patents - IPWatchdog.com
BioPharma Dive ٦ أبريل ٢٠٢٦ Under-the-skin Tepezza comparable to infused version in key study, Amgen says
Endpoints News ٦ أبريل ٢٠٢٦ Amgen seeks to buoy Tepezza with injectable data in face of incoming competition